Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 26, 2025, 1:29 pm

Market Cap	125 Cr.
Current Price	79.1
High / Low	145/70.1
Stock P/E	18.1
Book Value	93.9
Dividend Yield	0.00 %
ROCE	8.20 %
ROE	4.76 %
Face Value	10.0
PEG Ratio	-0.74

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Mangalam Drugs and Organics Ltd

Competitors of Mangalam Drugs and Organics Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,565.29 Cr	1,158.58		103.22	194.43	0.31%	16.65%	15.19%	6.18

All Competitor Stocks of Mangalam Drugs and Organics Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	120.96	109.49	108.33	63.32	91.11	87.46	81.56	97.34	102.24	76.53	79.94	88.71	73.04
Expenses	110.77	99.12	99.89	56.84	90.87	90.94	79.37	90.36	90.54	68.34	71.25	79.94	62.88
Operating Profit	10.19	10.37	8.44	6.48	0.24	-3.48	2.19	6.98	11.70	8.19	8.69	8.77	10.16
OPM %	8.42%	9.47%	7.79%	10.23%	0.26%	-3.98%	2.69%	7.17%	11.44%	10.70%	10.87%	9.89%	13.91%
Other Income	0.00	0.01	0.00	0.13	0.29	0.02	0.03	0.00	0.05	0.02	0.14	0.13	0.21
Interest	2.53	3.54	2.56	3.22	3.43	3.41	3.24	3.31	3.95	3.75	3.67	3.49	4.03
Depreciation	2.69	2.60	2.76	2.88	2.75	3.42	3.73	3.62	3.86	3.87	3.97	3.93	4.61
Profit before tax	4.97	4.24	3.12	0.51	-5.65	-10.29	-4.75	0.05	3.94	0.59	1.19	1.48	1.73
Tax %	-34.61%	29.01%	28.85%	15.69%	-22.30%	-7.29%	-25.05%	-920.00%	9.90%	-355.93%	-125.21%	5.41%	90.75%
Net Profit	6.69	3.00	2.23	0.43	-4.39	-9.54	-3.56	0.50	3.55	2.68	2.69	1.40	0.15
EPS in Rs	4.23	1.90	1.41	0.27	-2.77	-6.03	-2.25	0.32	2.24	1.69	1.70	0.88	0.09

Last Updated: May 31, 2025, 8:29 am

Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 73.04 Cr.. The value appears to be declining and may need further review. It has decreased from 88.71 Cr. (Dec 2024) to 73.04 Cr., marking a decrease of 15.67 Cr..
For Expenses, as of Mar 2025, the value is 62.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 79.94 Cr. (Dec 2024) to 62.88 Cr., marking a decrease of 17.06 Cr..
For Operating Profit, as of Mar 2025, the value is 10.16 Cr.. The value appears strong and on an upward trend. It has increased from 8.77 Cr. (Dec 2024) to 10.16 Cr., marking an increase of 1.39 Cr..
For OPM %, as of Mar 2025, the value is 13.91%. The value appears strong and on an upward trend. It has increased from 9.89% (Dec 2024) to 13.91%, marking an increase of 4.02%.
For Other Income, as of Mar 2025, the value is 0.21 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Dec 2024) to 0.21 Cr., marking an increase of 0.08 Cr..
For Interest, as of Mar 2025, the value is 4.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.49 Cr. (Dec 2024) to 4.03 Cr., marking an increase of 0.54 Cr..
For Depreciation, as of Mar 2025, the value is 4.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.93 Cr. (Dec 2024) to 4.61 Cr., marking an increase of 0.68 Cr..
For Profit before tax, as of Mar 2025, the value is 1.73 Cr.. The value appears strong and on an upward trend. It has increased from 1.48 Cr. (Dec 2024) to 1.73 Cr., marking an increase of 0.25 Cr..
For Tax %, as of Mar 2025, the value is 90.75%. The value appears to be increasing, which may not be favorable. It has increased from 5.41% (Dec 2024) to 90.75%, marking an increase of 85.34%.
For Net Profit, as of Mar 2025, the value is 0.15 Cr.. The value appears to be declining and may need further review. It has decreased from 1.40 Cr. (Dec 2024) to 0.15 Cr., marking a decrease of 1.25 Cr..
For EPS in Rs, as of Mar 2025, the value is 0.09. The value appears to be declining and may need further review. It has decreased from 0.88 (Dec 2024) to 0.09, marking a decrease of 0.79.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:50 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	123	221	295	299	269	228	282	380	451	372	369	318
Expenses	113	200	257	252	222	218	259	327	402	347	351	282
Operating Profit	10	20	38	47	47	10	24	53	49	26	17	36
OPM %	8%	9%	13%	16%	17%	4%	8%	14%	11%	7%	5%	11%
Other Income	0	0	0	-0	1	0	1	5	0	0	0	0
Interest	10	10	9	10	12	9	10	9	11	13	14	15
Depreciation	4	4	4	5	7	7	8	9	10	11	15	16
Profit before tax	-4	6	24	31	29	-6	6	40	28	2	-11	5
Tax %	-22%	-2%	33%	29%	32%	40%	-32%	29%	29%	43%	-18%	-39%
Net Profit	-3	6	16	22	20	-8	8	28	20	1	-9	7
EPS in Rs	-2.31	4.66	11.15	14.08	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72	4.37
Dividend Payout %	0%	0%	0%	0%	4%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	300.00%	166.67%	37.50%	-9.09%	-140.00%	200.00%	250.00%	-28.57%	-95.00%	-1000.00%	177.78%
Change in YoY Net Profit Growth (%)	0.00%	-133.33%	-129.17%	-46.59%	-130.91%	340.00%	50.00%	-278.57%	-66.43%	-905.00%	1177.78%

Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	4%
5 Years:	2%
3 Years:	-11%
TTM:	-14%

Compounded Profit Growth
10 Years:	1%
5 Years:	-4%
3 Years:	-29%
TTM:	177%

Stock Price CAGR
10 Years:	4%
5 Years:	2%
3 Years:	-18%
1 Year:	-26%

Return on Equity
10 Years:	9%
5 Years:	7%
3 Years:	0%
Last Year:	5%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:44 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	13	13	14	16	16	16	16	16	16	16	16	16
Reserves	10	16	47	70	88	80	88	115	135	136	127	133
Borrowings	77	78	60	66	69	65	52	70	88	89	106	89
Other Liabilities	25	63	38	38	54	50	75	64	90	117	109	121
Total Liabilities	125	170	160	190	227	211	231	264	328	358	357	359
Fixed Assets	53	53	54	93	102	103	101	118	135	142	147	158
CWIP	0	0	5	0	0	0	1	6	6	9	8	0
Investments	0	0	0	2	0	0	0	0	0	0	0	0
Other Assets	72	117	100	95	125	107	128	140	188	206	202	201
Total Assets	125	170	160	190	227	211	231	264	328	358	357	359

Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
For Reserves, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 6.00 Cr..
For Borrowings, as of Mar 2025, the value is 89.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 106.00 Cr. (Mar 2024) to 89.00 Cr., marking a decrease of 17.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 109.00 Cr. (Mar 2024) to 121.00 Cr., marking an increase of 12.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 158.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Mar 2024) to 158.00 Cr., marking an increase of 11.00 Cr..
For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 8.00 Cr..
For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Mar 2025, the value is 201.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Mar 2024) to 201.00 Cr., marking a decrease of 1.00 Cr..
For Total Assets, as of Mar 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..

Notably, the Reserves (133.00 Cr.) exceed the Borrowings (89.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	7	14	22	43	25	22	31	28	26	38	12	43
Cash from Investing Activity +	-2	-4	-11	-39	-16	-9	-7	-31	-27	-22	-18	-19
Cash from Financing Activity +	-5	-10	-11	-3	-9	-11	-23	3	3	-17	6	-22
Net Cash Flow	0	1	-0	0	-0	1	0	-1	1	-1	-0	2

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-67.00	-58.00	-22.00	-19.00	-22.00	-55.00	-28.00	-17.00	-39.00	-63.00	-89.00	-53.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	70	88	73	37	45	61	28	52	52	38	46	28
Inventory Days	112	170	134	85	69	132	175	121	85	139	200	185
Days Payable	39	97	128	37	38	82	77	106	63	65	139	124
Cash Conversion Cycle	144	161	79	85	75	111	126	67	74	112	107	88
Working Capital Days	125	122	79	76	70	99	102	66	75	84	93	97
ROCE %	-7%	6%	16%	29%	31%	25%	2%	11%	27%	18%	6%	1%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	50.53%	50.42%	50.41%	50.31%	50.31%	50.31%	50.31%	50.31%	50.31%	50.31%	50.30%	50.30%
FIIs	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.26%	0.21%	0.11%	0.11%
DIIs	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	49.36%	49.47%	49.49%	49.58%	49.59%	49.58%	49.59%	49.59%	49.42%	49.47%	49.58%	49.58%
No. of Shareholders	20,084	18,988	18,483	17,911	17,943	17,890	17,978	18,610	19,173	19,312	19,508	19,679

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24
FaceValue	10.00
Basic EPS (Rs.)	-5.73
Diluted EPS (Rs.)	-5.73
Cash EPS (Rs.)	3.52
Book Value[Excl.RevalReserv]/Share (Rs.)	85.79
Book Value[Incl.RevalReserv]/Share (Rs.)	85.79
Revenue From Operations / Share (Rs.)	232.87
PBDIT / Share (Rs.)	11.05
PBIT / Share (Rs.)	1.80
PBT / Share (Rs.)	-7.00
Net Profit / Share (Rs.)	-5.73
NP After MI And SOA / Share (Rs.)	-5.73
PBDIT Margin (%)	4.74
PBIT Margin (%)	0.77
PBT Margin (%)	-3.00
Net Profit Margin (%)	-2.46
NP After MI And SOA Margin (%)	-2.46
Return on Networth / Equity (%)	-6.68
Return on Capital Employeed (%)	1.67
Return On Assets (%)	-2.71
Long Term Debt / Equity (X)	0.09
Total Debt / Equity (X)	0.64
Current Ratio (X)	1.07
Quick Ratio (X)	0.31
Interest Coverage Ratio (X)	1.26
Interest Coverage Ratio (Post Tax) (X)	0.34
Enterprise Value (Cr.)	233.41
EV / Net Operating Revenue (X)	0.63
EV / EBITDA (X)	13.34
MarketCap / Net Operating Revenue (X)	0.39
Price / BV (X)	1.08
Price / Net Operating Revenue (X)	0.39
EarningsYield	-0.06

After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Cash EPS (Rs.), as of Mar 24, the value is 3.52. This value is within the healthy range. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.79. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.79. No previous period data is available for comparison.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 232.87. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 24, the value is 11.05. This value is within the healthy range. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 24, the value is 1.80. This value is within the healthy range. No previous period data is available for comparison.
For PBT / Share (Rs.), as of Mar 24, the value is -7.00. This value is below the healthy minimum of 0. No previous period data is available for comparison.
For Net Profit / Share (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For PBDIT Margin (%), as of Mar 24, the value is 4.74. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For PBIT Margin (%), as of Mar 24, the value is 0.77. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For PBT Margin (%), as of Mar 24, the value is -3.00. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Net Profit Margin (%), as of Mar 24, the value is -2.46. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.46. This value is below the healthy minimum of 8. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 24, the value is -6.68. This value is below the healthy minimum of 15. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 24, the value is 1.67. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 24, the value is -2.71. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
For Total Debt / Equity (X), as of Mar 24, the value is 0.64. This value is within the healthy range. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 24, the value is 1.07. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.26. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.34. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 24, the value is 233.41. No previous period data is available for comparison.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 24, the value is 13.34. This value is within the healthy range. No previous period data is available for comparison.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For Price / BV (X), as of Mar 24, the value is 1.08. This value is within the healthy range. No previous period data is available for comparison.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For EarningsYield, as of Mar 24, the value is -0.06. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Mangalam Drugs and Organics Ltd as of June 26, 2025 is: 66.01

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 26, 2025, Mangalam Drugs and Organics Ltd is Overvalued by 16.55% compared to the current share price 79.10

Intrinsic Value of Mangalam Drugs and Organics Ltd as of June 26, 2025 is: 49.92

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 26, 2025, Mangalam Drugs and Organics Ltd is Overvalued by 36.89% compared to the current share price 79.10

Last 5 Year EPS CAGR: -24.38%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (87.08 cr) compared to borrowings (75.75 cr), indicating strong financial stability. The company has shown consistent growth in sales (300.58 cr) and profit (12.50 cr) over the years.	The stock has a low average ROCE of 13.75%, which may not be favorable. The stock has a high average Working Capital Days of 90.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 102.42, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
1. Net Profit Margin: -2.46%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 1.67% (Industry Average ROCE: 16.51%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -6.68% (Industry Average ROE: 14.69%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.34
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.31
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 18.1 (Industry average Stock P/E: 86.3)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.64
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 318.23 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Rupam Building, 3rd Floor, 239, P.D. Mello Road, Mumbai Maharashtra 400001	contactus@mangalamdrugs.com http://www.mangalamdrugs.com

Management
Name	Position Held
Mr. Govardhan Murlidhar Dhoot	Chairman & Managing Director
Mr. Brijmohan Murlidhar Dhoot	Whole Time Director
Mr. Rakesh Kishinchand Milwani	Non Exe.Non Ind.Director
Mr. Rukmesh Prabhukumar Dhandhania	Independent Director
Mrs. Nidhi Shantanu Mundada	Independent Director
Mr. Praveen Saxena	Independent Director

FAQ

What is the intrinsic value of Mangalam Drugs and Organics Ltd?

Mangalam Drugs and Organics Ltd's intrinsic value (as of 26 June 2025) is 66.01 — 16.55% lower the current market price of 79.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 125 Cr. market cap, FY2025-2026 high/low of 145/70.1, reserves of 133 Cr, and liabilities of 359 Cr.

What is the Market Cap of Mangalam Drugs and Organics Ltd?

The Market Cap of Mangalam Drugs and Organics Ltd is 125 Cr..

What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 26 June 2025?

The current stock price of Mangalam Drugs and Organics Ltd as on 26 June 2025 is 79.1.

What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is ₹145/70.1.

What is the Stock P/E of Mangalam Drugs and Organics Ltd?

The Stock P/E of Mangalam Drugs and Organics Ltd is 18.1.

What is the Book Value of Mangalam Drugs and Organics Ltd?

The Book Value of Mangalam Drugs and Organics Ltd is 93.9.

What is the Dividend Yield of Mangalam Drugs and Organics Ltd?

The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.

What is the ROCE of Mangalam Drugs and Organics Ltd?

The ROCE of Mangalam Drugs and Organics Ltd is 8.20 %.

What is the ROE of Mangalam Drugs and Organics Ltd?

The ROE of Mangalam Drugs and Organics Ltd is 4.76 %.

What is the Face Value of Mangalam Drugs and Organics Ltd?

The Face Value of Mangalam Drugs and Organics Ltd is 10.0.